ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 671,34
0,00%
Dow Jones
39 134,76
0,77%
DAX
18 254,18
1,03%
Brent Oil
84,945
-0,07%
Bitcoin
64 504,20
-0,49%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. NovoCure Ltd (NVCR)

  7. NovoCure Ltd (NVCR) Actualités

NVCR NovoCure Ltd

19,69
0,25 (1,29%)
21 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
NovoCure Ltd NVCR NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,25 1,29% 19,69 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
19,20 19,12 19,85 19,175 19,44
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
10/6/202422:09EDGAR2Form 8-K - Current report
07/6/202400:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/6/202400:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/6/202423:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/6/202414:00BWMETIS Phase 3 Clinical Trial Met Primary Endpoint..
24/5/202415:06BWTIGER-Studie berichtet über neue Überlebensergebnisse der..
23/5/202423:05BWTIGER Study Reports New TTFields Therapy Survival Results..
20/5/202414:01EDGAR2Form 8-K - Current report
02/5/202413:01BWNovocure Secures New $400 Million Multi-Tranche Non-Dilutive..
02/5/202413:00BWNovocure Reports First Quarter 2024 Financial Results
24/4/202416:45BWResults of Novocure’s METIS Phase 3 Clinical Trial for..
05/4/202413:00BWNovocure Announces 20 Presentations On Tumor Treating..
01/4/202413:00BWNovocure to Report First Quarter 2024 Financial Results
29/3/202401:07BWMETIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
28/3/202418:51BWKlinische Phase-3-Studie METIS erreicht primären Endpunkt..
28/3/202418:50BWL’essai clinique de phase 3 METIS a atteint son critère..
27/3/202412:00BWMETIS Phase 3 Clinical Trial Met Primary Endpoint,..
11/3/202412:00BWINNOVATE-3 Late Breaking Abstract Selected as a Best Oral..
05/3/202422:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202400:39EDGAR2Form 144 - Report of proposed sale of securities
04/3/202423:56EDGAR2Form 144 - Report of proposed sale of securities
01/3/202423:06EDGAR2Form 144 - Report of proposed sale of securities
01/3/202423:01EDGAR2Form 144 - Report of proposed sale of securities
29/2/202422:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202422:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202422:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202422:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202413:11EDGAR2Form S-8 - Securities to be offered to employees in employee..
22/2/202413:06EDGAR2Form 8-K - Current report
22/2/202413:05EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
22/2/202413:00BWNovocure Reports Fourth Quarter and Full Year 2023 Financial..
18/1/202417:10DJNNovocure Shares Rise 17% After FDA Accepts Pre-Market..
18/1/202413:01EDGAR2Form 8-K - Current report
18/1/202413:00BWNovocure Announces FDA Acceptance of the PMA Application for..
12/1/202422:57EDGAR2Form 3 - Initial statement of beneficial ownership of..
09/1/202413:00EDGAR2Form 8-K - Current report
09/1/202413:00BWNovocure Announces Last Patient Enrolled in Phase 3 TRIDENT..
08/1/202413:10EDGAR2Form 8-K - Current report
08/1/202413:00BWNovocure Announces Preliminary Full Year and Fourth Quarter..
04/1/202422:10EDGAR2Form 8-K - Current report
04/1/202422:05BWNovocure Appoints Dr. Nicolas Leupin as Chief Medical..
27/12/202313:00BWNovocure to Participate in 42nd Annual J.P. Morgan..
28/11/202313:30EDGAR2Form 8-K - Current report
28/11/202313:30BWNovocure Announces Portfolio Prioritization and Strategic..
21/11/202313:00BWNovocure to Participate in 35th Annual Piper Sandler..
10/11/202314:00BWNovocure Announces Presentations on Tumor Treating Fields..
08/11/202322:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/11/202321:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/11/202321:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Dernières Valeurs Consultées

NASDAQ
NVCR
NovoCure
BIT
P1J7C3
BNP Paribas Issuance
LSE
36AZ
Sthn.pac 5a2aa
NYSE
DMH
Ducati Motor
TG
R86E
RCI Banque
BIT
P1IA85
BNP Paribas Issuance
COIN
TRLFUST
BIT
S27191
Societe Generale Effekten
LSE
87BR
Lloyds Bk. 14
TSX
JAG
Jaguar Mining
EU
BE0002791722
City of Brussels 0.248% ...
COIN
BLYBTC
Blocery Token
BIT
P1Q009
BNP Paribas Issuance
USOTC
MTSFY
Mitsui Fudosan (PK)
BIT
P1TGM3
NLBNPIT1TGM3 20240621 12
BIT
UC8K37
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés